Gregory A Demopulos

Type: Person
Name: Gregory A Demopulos
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Omeros receives FDA clearance for thrombotic microangiopathies drug

Omeros Corporation, a biopharmaceutical company, has announced that its investigational new drug application, or IND, to evaluate OMS721 for the inhibition of complement-mediated thrombotic microangiopathies, or TMAs, has received clearance from the FDA. ... [Published Individual.com - Apr 14 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic Microangiopathies

By a News Reporter-Staff News Editor at Biotech Week -- Omeros Corporation (NASDAQ: OMER) announced that its Investigational New Drug Application (IND) to evaluate OMS721 for the inhibition of complement?mediated thrombotic microangiopathies (TMAs) has ... [Published HispanicBusiness.com - Apr 10 2014]
First reported Apr 07 2014 - Updated Apr 08 2014 - 2 reports

Omeros to Present at the 13th Annual Needham Healthcare Conference

PR NewswireSEATTLE, April 7, 2014SEATTLE , April 7, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of ... [Published Reuters - Apr 07 2014]
First reported Apr 03 2014 - Updated Apr 04 2014 - 85 reports

Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic Microangiopathies

SOURCE Omeros Corporation-- Phase 2 Clinical Trial Planned to Begin This Quarter --SEATTLEFDA's clearance of the IND allows the initiation of the Phase 2 program for OMS721, which will assess the efficacy and safety of OMS721 in patients with disorders ... [Published KMPH Fox 26 - Apr 03 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 1 reports

Omeros to Present at BioCentury Future Leaders in the Biotech Industry Conference

(NewsRx) -- By a News Reporter-Staff News Editor at Biotech Business Week -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders ... [Published NewsRX - Mar 28 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 3 reports

Omeros to Present at BioCentury Future Leaders in the Biotech Industry Conference

/PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory ... [Published BioPortfolio - Mar 21 2014]
First reported Mar 13 2014 - Updated Mar 14 2014 - 1 reports

Omeros Corporation Reports Fourth Quarter and Year-End 2013 Financial Results

"Omeros achieved a number of significant milestones in 2013," said Gregory A. DemopulosFourth Quarter and Recent HighlightsFinancial ResultsOperating expenses for the three months ended December 31, 2013 Operating expenses for the year ended December ... [Published ADVFN UK - Mar 13 2014]
First reported Mar 12 2014 - Updated Mar 12 2014 - 1 reports

Omeros : Submits IND to Advance OMS721 Phase 2 Clinical Program

By a News Reporter-Staff News Editor at Clinical Trials Week -- Omeros Corporation (NASDAQ: OMER) announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical ... [Published 4 Traders - Mar 12 2014]
First reported Mar 12 2014 - Updated Mar 12 2014 - 1 reports

Omeros : Reports Additional Positive Data from its OMS824 Phase 2a Schizophrenia Clinical Trial

By a News Reporter-Staff News Editor at Clinical Trials Week -- Omeros Corporation (NASDAQ: OMER) announced additional positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor. Patients with schizophrenia ... [Published 4 Traders - Mar 12 2014]
First reported Mar 07 2014 - Updated Mar 07 2014 - 1 reports

Omeros reports additional positive data from OMS824 Phase IIa schizophrenia clinical trial

Omeros has announced additional positive results from a Phase IIa clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor.Patients with schizophrenia were administered a higher dose than had been evaluated in any OMS824 trial, which ... [Published Pharmaceutical Business Review - Mar 07 2014]
First reported Feb 26 2014 - Updated Feb 26 2014 - 1 reports

Omeros to Present at Cowen and Company 34th Annual Health Care Conference

SEATTLE, Feb. 26, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today ... [Published PR Newswire: General Business - Feb 26 2014]
First reported Feb 21 2014 - Updated Feb 21 2014 - 1 reports

Omeros doses 1st patient in second phase II clinical trial of OMS824

Omeros Corporation, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecules, has dosed its first patient in a second phase II clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) ... [Published PharmaBiz - Feb 21 2014]

More Content

All (103) | News (101) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Omeros receives FDA clearance for thrombotic mi... [Published Individual.com - Apr 14 2014]
Investigational New Drug Application Cleared by... [Published HispanicBusiness.com - Apr 10 2014]
Omeros to Present at the 13th Annual Needham He... [Published Reuters - Apr 07 2014]
Omeros to Present at the 13th Annual Needham He... [Published Barchart - Apr 07 2014]
Investigational New Drug Application Cleared by... [Published KMPH Fox 26 - Apr 03 2014]
Investigational New Drug Application Cleared by... [Published WSFX-TV - Apr 03 2014]
Investigational New Drug Application Cleared by... [Published WFMJ 21 - TV - Apr 03 2014]
Investigational New Drug Application Cleared by... [Published ABC 12 WJRT - Apr 03 2014]
Investigational New Drug Application Cleared by... [Published WNEM - Apr 03 2014]
Investigational New Drug Application Cleared by... [Published WOWK - Apr 03 2014]
Investigational New Drug Application Cleared by... [Published WTOC TV - Apr 03 2014]
Investigational New Drug Application Cleared by... [Published Eyewitness News - Apr 03 2014]
Investigational New Drug Application Cleared by... [Published CBS 3 Springfield - Apr 03 2014]
Investigational New Drug Application Cleared by... [Published WCAX TV3 - Apr 03 2014]
Investigational New Drug Application Cleared by... [Published WLNS - Apr 03 2014]
Investigational New Drug Application Cleared by... [Published WBAY Green Bay - Apr 03 2014]
Investigational New Drug Application Cleared by... [Published KSWO - Apr 03 2014]
Investigational New Drug Application Cleared by... [Published KLTV 7 - Apr 03 2014]
Investigational New Drug Application Cleared by... [Published ABC 13 Toledo - Apr 03 2014]
Investigational New Drug Application Cleared by... [Published KSLA - Apr 03 2014]
Investigational New Drug Application Cleared by... [Published WMDT ABC-47 - Apr 03 2014]
Investigational New Drug Application Cleared by... [Published Live 5 WCSC - Apr 03 2014]
Investigational New Drug Application Cleared by... [Published NBC12 Online - Apr 03 2014]
Investigational New Drug Application Cleared by... [Published KPHO Phoenix - Apr 03 2014]
Investigational New Drug Application Cleared by... [Published KCEN HD - Apr 03 2014]
Investigational New Drug Application Cleared by... [Published WVNS - Apr 03 2014]
Investigational New Drug Application Cleared by... [Published KATV - Apr 03 2014]
Investigational New Drug Application Cleared by... [Published MyFoxTallahassee.com - Apr 03 2014]
Investigational New Drug Application Cleared by... [Published News 9 - Apr 03 2014]
Investigational New Drug Application Cleared by... [Published WIS-TV - Apr 03 2014]
1 2 3 4
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Omeros to Present at Cowen and Company 34th Ann... [Published PR Newswire: General Business - Feb 26 2014]
SEATTLE, Feb. 26, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today ...
1

Press Releases

sort by: Date | Relevance
Omeros Hires Michael K. Inouye to Lead Commerci... [Published PR Newswire - Oct 08 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.